title: The immunotherapy era of myeloma: monoclonal antibodies, vaccines, and adoptive T-cell therapies.
abstract: The treatment of multiple myeloma has evolved significantly over the last decades from primarily alkylator-based chemotherapeutic agents with minimal efficacy to the introduction of more effective agents including immune modulators and proteasome inhibitors, which have changed the landscape of therapy for this disease. We are now entering a new era that will increasingly integrate immunotherapy into standard treatment. This review discusses the current immune-based strategies currently approved, as well as various immune approaches being actively investigated including monoclonal antibodies, checkpoint inhibitors, vaccines, and adoptive T-cell therapies.
authors: Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University, Baltimore, MD.
authors: Valentina
authors: V
authors: Hoyos
authors: Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University, Baltimore, MD.
authors: Ivan
authors: 0000-0002-7316-8862
authors: I
authors: Borrello
mesh_terms: D000911:Antibodies, Monoclonal / Q000627:therapeutic use; D019496:Cancer Vaccines / Q000627:therapeutic use; D006801:Humans; D007108:Immune Tolerance; D007167:Immunotherapy / Q000379:methods* / Q000639:trends; D016219:Immunotherapy, Adoptive / Q000379:methods / Q000639:trends; D009101:Multiple Myeloma / Q000276:immunology* / Q000628:therapy*; D013601:T-Lymphocytes / Q000276:immunology
chemical_list: D000911:Antibodies, Monoclonal; D019496:Cancer Vaccines